Identification
Name Sulfoxone
Accession Number DB01145 (APRD00704)
Type small molecule
Description Sulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.
Structure
Categories (*)
Molecular Weight 404.482
Groups approved
Monoisotopic Weight 404.017048324
Pharmacology
Indication For the treatment of leprosy and dermatitis herpetiformis
Mechanism of action Sulfoxone is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. The normal substrate for the enzyme, para-aminobenzoic acid (PABA) cannot bind as usual. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Absorption Rapidly absorbed.
Protein binding 69%
Biotransformation Hepatic.
Route of elimination Not Available
Toxicity Oral, rat LD50: 7000 mg/kg
Affected organisms
  • Enteric bacteria and other eubacteria
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Dihydropteroate synthetase
Name Dihydropteroate synthetase
Gene Name Not Available
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Katz SI: - Sulfoxone (Diasone) sodium for dermatitis herpetiformis
  • Takahashi T: [Mutations of drug target molecules in Pneumocystis jirovecii isolates and future investigations] Nippon Ishinkin Gakkai Zasshi. 2009;50(2):67-73. - Pubmed
DTHybrid score 1.0586